WO2001009138A3 - Chemokine receptor antagonists and methods of use therefor - Google Patents

Chemokine receptor antagonists and methods of use therefor Download PDF

Info

Publication number
WO2001009138A3
WO2001009138A3 PCT/US2000/020732 US0020732W WO0109138A3 WO 2001009138 A3 WO2001009138 A3 WO 2001009138A3 US 0020732 W US0020732 W US 0020732W WO 0109138 A3 WO0109138 A3 WO 0109138A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
receptor antagonists
chemokine receptor
use therefor
therefor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/020732
Other languages
French (fr)
Other versions
WO2001009138A2 (en
Inventor
Jay R Luly
Yoshisuke Nakasato
Etsuo Ohshima
Hiroki Sone
Osamu Kotera
Geraldine C B Harriman
Kenneth G Carson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Millennium Pharmaceuticals Inc
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd, Millennium Pharmaceuticals Inc filed Critical Kyowa Hakko Kogyo Co Ltd
Priority to MXPA02000978A priority Critical patent/MXPA02000978A/en
Priority to KR1020027001177A priority patent/KR20020016926A/en
Priority to CA002391267A priority patent/CA2391267A1/en
Priority to BR0013065-6A priority patent/BR0013065A/en
Priority to HK02104294.3A priority patent/HK1044333A1/en
Priority to JP2001514341A priority patent/JP4903333B2/en
Priority to IL14785200A priority patent/IL147852A0/en
Priority to DE60041336T priority patent/DE60041336D1/en
Priority to AU63914/00A priority patent/AU6391400A/en
Priority to EA200200194A priority patent/EA200200194A1/en
Priority to EP00950880A priority patent/EP1204665B1/en
Publication of WO2001009138A2 publication Critical patent/WO2001009138A2/en
Publication of WO2001009138A3 publication Critical patent/WO2001009138A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12—[b,e]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)

Abstract

Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by (I) or (II) and physiologically acceptable salts thereof.
PCT/US2000/020732 1999-07-28 2000-07-28 Chemokine receptor antagonists and methods of use therefor Ceased WO2001009138A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MXPA02000978A MXPA02000978A (en) 1999-07-28 2000-07-28 Chemokine receptor antagonists and methods of use therefor.
KR1020027001177A KR20020016926A (en) 1999-07-28 2000-07-28 Chemokine receptor antagonists and methods of use therefor
CA002391267A CA2391267A1 (en) 1999-07-28 2000-07-28 Chemokine receptor antagonists and methods of use therefor
BR0013065-6A BR0013065A (en) 1999-07-28 2000-07-28 Method and compound to treat a disease associated with aberrant leukocyte recruitment and / or activation
HK02104294.3A HK1044333A1 (en) 1999-07-28 2000-07-28 Chemokine receptor antagonists and methods of use therefor
JP2001514341A JP4903333B2 (en) 1999-07-28 2000-07-28 Chemokine receptor antagonist and method of use thereof
IL14785200A IL147852A0 (en) 1999-07-28 2000-07-28 Chemokine receptor antagonists and pharmaceutical compositions containing the same
DE60041336T DE60041336D1 (en) 1999-07-28 2000-07-28 CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF THEIR APPLICATION
AU63914/00A AU6391400A (en) 1999-07-28 2000-07-28 Chemokine receptor antagonists and methods of use therefor
EA200200194A EA200200194A1 (en) 1999-07-28 2000-07-28 ANTAGONISTS OF THE CHEMOKINE RECEPTOR AND METHODS OF THEIR APPLICATION
EP00950880A EP1204665B1 (en) 1999-07-28 2000-07-28 Chemokine receptor antagonists and methods of use therefor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/362,837 1999-07-28
US09/362,837 US6509346B2 (en) 1998-01-21 1999-07-28 Chemokine receptor antagonists and methods of use therefor

Publications (2)

Publication Number Publication Date
WO2001009138A2 WO2001009138A2 (en) 2001-02-08
WO2001009138A3 true WO2001009138A3 (en) 2001-09-13

Family

ID=23427735

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/020732 Ceased WO2001009138A2 (en) 1999-07-28 2000-07-28 Chemokine receptor antagonists and methods of use therefor

Country Status (17)

Country Link
US (2) US6509346B2 (en)
EP (1) EP1204665B1 (en)
JP (1) JP4903333B2 (en)
KR (1) KR20020016926A (en)
CN (1) CN1471536A (en)
AT (1) ATE420090T1 (en)
AU (1) AU6391400A (en)
BR (1) BR0013065A (en)
CA (1) CA2391267A1 (en)
DE (1) DE60041336D1 (en)
EA (1) EA200200194A1 (en)
ES (1) ES2321798T3 (en)
HK (1) HK1044333A1 (en)
HU (1) HUP0202202A3 (en)
IL (1) IL147852A0 (en)
MX (1) MXPA02000978A (en)
WO (1) WO2001009138A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271176B2 (en) 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US9334283B2 (en) 2002-11-13 2016-05-10 Millennium Pharmaceuticals, Inc. CCR1 antagonists and methods of use thereof

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228314B1 (en) * 1998-09-04 2013-03-28 Millennium Pharmaceuticals Chemokine receptor antagonists, their use and pharmaceutical compositions containing them
US6919313B2 (en) * 2001-03-30 2005-07-19 President & Fellows Of Harvard College Protein waving a PDZ and a RGS domain
CN1911930A (en) * 2001-11-21 2007-02-14 千禧药品公司 Chemokine receptor anagonists, methods and use therefor
EP1553098A1 (en) * 2002-10-18 2005-07-13 Ono Pharmaceutical Co., Ltd. Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
ES2665464T3 (en) * 2003-03-28 2018-04-25 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
MY140489A (en) * 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
CN100526301C (en) * 2003-12-26 2009-08-12 卫材R&D管理有限公司 1,2-bis(cyclo)substituted benzene compounds
US7410971B2 (en) * 2003-12-26 2008-08-12 Eisai R&D Management Co., Ltd. 1,2-di(cyclic)substituted benzene compounds
US20060276465A1 (en) * 2003-12-26 2006-12-07 Eisai R&D Management Co., Ltd. 1,2-di(cyclic) substituted benzene compounds
DE102004004719A1 (en) * 2004-01-29 2005-08-18 Basf Ag Process for the preparation of enantiomerically pure aminoalcohols
EP1802287A2 (en) * 2004-09-27 2007-07-04 Sigmoid Biotechnologies Limited Minicapsule formulations
US7960549B2 (en) * 2004-12-17 2011-06-14 Carole Neves Solid forms of a chemokine receptor antagonist and methods of use thereof
CN101068798B (en) 2004-12-20 2010-05-12 卫材R&D管理有限公司 1-Cyclopropylmethyl-4-[2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine salts and crystals
MY144974A (en) * 2005-06-14 2011-11-30 Eisai R&D Man Co Ltd 1,2-di(cyclic) substituted benzene derivatives
ES2393814T3 (en) 2007-04-04 2012-12-28 Sigmoid Pharma Limited An oral pharmaceutical composition
CA2685118C (en) * 2007-04-26 2016-11-01 Sigmoid Pharma Limited Manufacture of multiple minicapsules
WO2008132712A2 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Combination pharmaceutical compositions
US20090286823A1 (en) * 2007-12-17 2009-11-19 Millennium Pharmaceuticals Inc. CCR1 Inhibitors useful for the treatment of multiple myeloma and other disorders
ES2530049T3 (en) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composition comprising drops of oil
CN102573802A (en) 2009-08-12 2012-07-11 希格默伊德药业有限公司 Immunomodulatory compositions comprising a polymer matrix and an oil phase
WO2011137331A2 (en) * 2010-04-30 2011-11-03 Kinentia Biosciences Llc 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
KR101102335B1 (en) * 2011-09-06 2012-01-03 (주)칠칠공사 Adjustable pool for swimming practice
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
JP6716582B2 (en) 2014-11-07 2020-07-01 サブリミティ・セラピューティクス・リミテッドＳｕｂｌｉｍｉｔｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ Composition containing cyclosporine
CN115389659B (en) * 2022-08-23 2024-07-16 浙江中医药大学 Cell membrane bonded magnetic carbon sphere composite material and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016226A1 (en) * 1991-03-19 1992-10-01 Smithkline Beecham Corporation Il-1 inhibitors
WO1997044329A1 (en) * 1996-05-20 1997-11-27 Teijin Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
WO1999037651A1 (en) * 1998-01-21 1999-07-29 Millenium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE80449C (en)
GB1003292A (en) 1960-12-08 1965-09-02 Sandoz Ag Improvements in or relating to 4-azathiaxanthene derivatives
NL132137C (en) * 1963-04-24
FR145F (en) 1964-06-01
CH421138A (en) 1965-11-04 1966-09-30 Wander Ag Dr A Process for the preparation of thioxanthene derivatives
US3409621A (en) 1966-04-01 1968-11-05 Schering Corp Piperazino-aza-dibenzo-[a, d]-cycloheptenes
US3625974A (en) 1967-04-28 1971-12-07 Fujisawa Pharmaceutical Co Dibenzothiazepine derivatives
NL6905642A (en) 1968-04-12 1969-10-14
DE2163657A1 (en) 1970-12-22 1972-07-13 Yoshitomi Pharmaceutical Industries Ltd., Osaka (Japan) N-substituted piperidine compounds
GB1330966A (en) 1970-12-22 1973-09-19 Yoshitomi Pharmaceutical N-substituted piperidine compounds methods for their production and pharmaceutical compositions containing them
CA1010870A (en) 1972-12-08 1977-05-24 Niels Lassen Thiaxanthene derivative and method
US4250176A (en) 1976-12-21 1981-02-10 Janssen Pharmaceutica N.V. Piperazine derivatives
US4335122A (en) 1981-03-18 1982-06-15 Hoechst-Roussel Pharmaceuticals Inc. Dihydro-dibenzoxepines-thiepines and -morphanthridones, compositions and use
DE3326641A1 (en) 1982-07-27 1984-02-02 Basf Ag, 6700 Ludwigshafen 5,6-Dihydro-11H-morphanthridin-6-ones, their preparation and medicaments containing these
US4547496A (en) 1983-06-24 1985-10-15 Kyowa Hakko Kogyo Co., Ltd. Antiulcer [1] benzepino[3,4-b]pyridine and compositions
DE3402060A1 (en) 1984-01-21 1985-08-01 Dr. Karl Thomae Gmbh, 7950 Biberach SUBSTITUTED 5,11-DIHYDRO-6H-DIBENZ (B, E) AZEPIN-6-ONE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
JPH0665664B2 (en) 1985-01-18 1994-08-24 大塚製薬株式会社 Morphoanthridine derivative
SE8500273D0 (en) 1985-01-22 1985-01-22 Leo Ab NEW TRICYCLIC ASSOCIATIONS, COMPOSITIONS CONTAINING SUCH ASSOCIATIONS, MANUFACTURING PROCEDURES AND METHODS OF TREATMENT
JPS6310784A (en) 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd Dibenz(b,e)oxepin derivative, antiallergic agent and anti-inflammatory agent
AU604726B2 (en) * 1986-06-26 1991-01-03 Kyowa Hakko Kogyo Co. Ltd. Antiarrhythmic agent
US5089496A (en) 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
IT8721978A0 (en) 1987-09-21 1987-09-21 Angeli Inst Spa NEW TRICYCLIC AMIDE DERIVATIVES.
US4882351A (en) 1987-10-14 1989-11-21 Roussel Uclaf Tricyclic compounds
AU612437B2 (en) 1987-12-14 1991-07-11 Kyowa Hakko Kogyo Co. Ltd. Tricyclic compounds
WO1989010369A1 (en) 1988-04-28 1989-11-02 Schering Corporation Novel benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use
US5242931A (en) 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
US4999363A (en) 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
DE3838912A1 (en) 1988-11-17 1990-05-23 Thomae Gmbh Dr K MEANS FOR THE TREATMENT OF ACUTE AND CHRONIC OBSTRUCTIVE RESPIRATORY DISEASES
JPH0694464B2 (en) 1991-01-23 1994-11-24 協和醗酵工業株式会社 Tricyclic compound and its intermediate
EP0511477B1 (en) 1991-03-11 1996-07-10 Kyowa Hakko Kogyo Co., Ltd. Indole derivatives
WO1992020681A1 (en) 1991-05-23 1992-11-26 Schering Corporation Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use
EP0524784A1 (en) 1991-07-23 1993-01-27 Schering Corporation Benzopyrido piperidylidene compounds as PAF antagonists
US5378701A (en) 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
US5679703A (en) 1992-09-16 1997-10-21 Kyowa Hakko Kogyo, Co., Ltd. Tricyclic compounds having ACAT inhibiting activity
US5538986A (en) 1993-12-06 1996-07-23 Schering Corporation Tricyclic derivatives, compositions and methods of use
MY113463A (en) 1994-01-04 2002-03-30 Novo Nordisk As Novel heterocyclic compounds
AU5271096A (en) 1995-04-07 1996-10-23 Novo Nordisk A/S Novel heterocyclic compounds
UA54385C2 (en) 1995-04-07 2003-03-17 Ново Нордіск А/С N-substituted azaheterocyclic carboxylic acids and etHers thereof, a method for THEIR PREPARATION, a pharmaceutical composition and a method for treatment
US5801175A (en) 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
AU5270796A (en) 1995-04-07 1996-10-23 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters th ereof
US5712280A (en) 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
JPH0940662A (en) 1995-05-24 1997-02-10 Kyowa Hakko Kogyo Co Ltd Tricyclic compound
EP0974583B1 (en) 1995-09-13 2002-05-29 Kyowa Hakko Kogyo Co., Ltd. Phenylpiperidine derivatives
WO1997024325A1 (en) 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
AU729415B2 (en) 1996-07-12 2001-02-01 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6323206B1 (en) 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
EP0916668A4 (en) 1996-07-29 2000-08-16 Banyu Pharma Co Ltd CHEMOKINE RECEPTOR ANTAGONISTS
AU4801197A (en) 1996-09-13 1998-04-02 Schering Corporation Tricyclic antitumor compounds being farnesyl protein transferase inhibit ors
CN1237176A (en) 1996-09-13 1999-12-01 先灵公司 Tricyclic compounds useful as FPT inhibitors
BR9712819A (en) 1996-09-13 1999-11-23 Schering Corp Tricyclic compounds useful for inhibiting protein g function and for treating proliferative diseases
SK33099A3 (en) 1996-09-13 2000-05-16 Schering Corp Novel tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase
ES2235252T3 (en) 1996-09-13 2005-07-01 Schering Corporation TRICICLIC INHIBITORS OF FARNESIL PROTEINA TRANSFERASA.
ATE294172T1 (en) 1996-09-13 2005-05-15 Schering Corp SUBSTITUTED BENZOCYCLOHEPTAPYRIDINE DERIVATIVES USABLE AS FARNESYL-PROTEIN TRANSFERASE INHIBITORS
JP2001500508A (en) 1996-09-13 2001-01-16 シェーリング コーポレイション Substituted benzocycloheptapyridine derivatives useful for inhibiting farnesyl protein transferase
CZ114199A3 (en) 1996-10-04 1999-09-15 Novo Nordisk A/S N-substituted azaheterocyclic compounds
AU5604998A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
WO1998025605A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998027815A1 (en) 1996-12-20 1998-07-02 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
WO1998043638A1 (en) 1997-03-27 1998-10-08 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for autoimmune diseases
HUP0002461A3 (en) 1997-04-15 2003-01-28 Kyowa Hakko Kogyo Kk Tricyclic benzothiepin a benzoxepin derivatives and pharmaceutical compositions thereof
US5877177A (en) 1997-06-17 1999-03-02 Schering Corporation Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6040318A (en) 1997-06-25 2000-03-21 Novo Nordisk A/S Tricycle substituted with azaheterocyclic carboxylic acids
US6048856A (en) 1997-12-17 2000-04-11 Novo Nordisk A/S Heterocyclic compounds
CA2318088A1 (en) 1998-01-21 1999-07-29 Yoshisuke Nakasato Chemokine receptor antagonists and methods of use therefor
US6613905B1 (en) * 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO2000014089A1 (en) 1998-09-04 2000-03-16 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016226A1 (en) * 1991-03-19 1992-10-01 Smithkline Beecham Corporation Il-1 inhibitors
WO1997044329A1 (en) * 1996-05-20 1997-11-27 Teijin Limited Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
WO1999037651A1 (en) * 1998-01-21 1999-07-29 Millenium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271176B2 (en) 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US9334283B2 (en) 2002-11-13 2016-05-10 Millennium Pharmaceuticals, Inc. CCR1 antagonists and methods of use thereof

Also Published As

Publication number Publication date
US6509346B2 (en) 2003-01-21
CN1471536A (en) 2004-01-28
IL147852A0 (en) 2002-08-14
BR0013065A (en) 2002-07-30
HUP0202202A2 (en) 2002-11-28
ES2321798T3 (en) 2009-06-12
DE60041336D1 (en) 2009-02-26
EA200200194A1 (en) 2002-08-29
HK1044333A1 (en) 2002-10-18
CA2391267A1 (en) 2001-02-08
JP2003506377A (en) 2003-02-18
KR20020016926A (en) 2002-03-06
EP1204665A2 (en) 2002-05-15
EP1204665B1 (en) 2009-01-07
AU6391400A (en) 2001-02-19
US20020119973A1 (en) 2002-08-29
WO2001009138A2 (en) 2001-02-08
JP4903333B2 (en) 2012-03-28
ATE420090T1 (en) 2009-01-15
US20030045516A1 (en) 2003-03-06
MXPA02000978A (en) 2002-08-12
HUP0202202A3 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
WO2001009138A3 (en) Chemokine receptor antagonists and methods of use therefor
ID26618A (en) CHEMOKINE RECEPTOR ANTAGONISTS AND THE METHOD OF USE
WO1998002151A3 (en) Chemokine receptor antagonists and methods of use therefor
CA2326804A1 (en) Compounds with activity on muscarinic receptors
EP1574219A3 (en) Method of inhibiting fibrosis with a somatostatin agonist
EA200101156A1 (en) DRUG COMPOSITIONS OF A NEW TYPE ON THE BASIS OF POSSESSING HOLYNTHERGIC ACTION OF COMPOUNDS AND β-MIMETIC
BRPI0108977B8 (en) azacyclic compounds, pharmaceutical composition and use of a compound or pharmaceutically acceptable salt thereof
WO1999004772A3 (en) Use of levobupivacaine
WO2002085861A8 (en) Imidazolidine compounds and their use as cxcr3 antagonists
CA2326339A1 (en) Use of dexmedetomidine for icu sedation
HK1044483A1 (en) Il-8 receptor antagonists
WO2003045942A3 (en) Chemokine receptor antagonists and methods of use thereof
WO2001009119A3 (en) Chemokine receptor antagonists
EA200000693A1 (en) ANTAGONISTS OF THE CHEMOKINE RECEPTOR AND METHODS OF THEIR APPLICATION
SG165152A1 (en) Chemokine receptor antagonists and methods of use thereof
EE200300129A (en) Use of distamycin alpha-haloacryloyl derivative
CA2322229A1 (en) Compositions comprising heparin and soluble tnf receptors for inhibition of tnf activity
HU9700661D0 (en) Use of alpha-1-adrenoreceptor antagonists for profilacting and treating cancer
WO2001009094A3 (en) Chemokine receptor antagonists and methods of use therefor
WO2000076500A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
HK1044717A1 (en) Il-8 receptor antagonists
WO2000044408A3 (en) Method of treating demyelinating inflammatory disease using ccr1 antagonists
MY133957A (en) "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor"
AU1209501A (en) Method for treating parkinson's disease by administering (-)-5-keto-2-n,n-di-n-propylamino-tetrahydrotetralin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 63914/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2391267

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 516794

Country of ref document: NZ

Ref document number: 147852

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020027001177

Country of ref document: KR

Ref document number: PA/a/2002/000978

Country of ref document: MX

Ref document number: IN/PCT/2002/00106/DE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2000950880

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200200194

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1200200199

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1020027001177

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 008131481

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2000950880

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642